SAN DIEGO, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Ziyen Energy has announced they have acquired the minerals at the Douglas Prospect, Saxet Field in Nueces County, Texas in exchange for 930,000 ZiyenCoins.

The Douglas Prospect, covers 83.19 gross acres, 15.6 mineral acres, and includes a recently drilled shut in oil well.  The Douglas Prospect is in the Saxet Oil Field which has produced over 100,000,000 barrels of oil from approximately 40 separate reservoirs. The field was developed in the late 1930’s producing an approximate 17,000 barrels of oil per day.

Alastair Caithness, CEO, stated

“This is our third transaction in ZiyenCoin, and the first acquisition in owning the mineral rights.  This will provide Ziyen Energy with a long-term asset for the company, as unlike leasing the property the company now owns the minerals indefinitely in a Texas oil field which has produced over 100 million barrels of oil.  As we make every new transaction in ZiyenCoin we are starting to set a precedence on the pricing of each oil asset with our digital energy token.”

Learn more about Ziyen Inc. and ZiyenCoin by reading our 2019 Ziyen Inc. Corporate Overview.

If you would like a copy of ZiyenCoin’s Security Token Offering (STO), then please email This email address is being protected from spambots. You need JavaScript enabled to view it. or visit www.ziyen.com for more information.

About Ziyen Energy:

Ziyen Energy. is a technology-driven energy company incorporated in the State of Wyoming, U.S.A. in April 2016. Originally formed as a software company providing information on the oil, gas, power and energy sectors, Ziyen specializes on business information, contracts, news and information by developing cutting edge procurement and supply chain software to provide clients with intelligence on industry specific government and private contracts. In addition, Ziyen Energy currently owns interests in oil assets based in Texas and the Illinois Basin, which covers Illinois, Indiana and Kentucky. The equity of Ziyen Energy has been tokenized and issued as ZiyenCoin which is offered for sale as a Security Token pursuant to SEC Rule 506(c) of Regulation D.

For more information visit www.ziyen.com

Forward Looking Statements:

Certain statements in this press release including, but not limited to, statements related to anticipated commencement of commercial production, targeted pricing, performance goals, and statements that otherwise relate to future periods are forward-looking statements. These statements involve risks and uncertainties, which are described in more detail in reports filed with the SEC. Forward-looking statements are made and based on information available to the company on the date of this press release. Ziyen Inc. assumes no obligation to update the information in this press release.

Contact:

Alastair Caithness

Media Relations

This email address is being protected from spambots. You need JavaScript enabled to view it.

CHARLOTTESVILLE, Va., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its previously announced registered direct offering, priced at-the-market, with certain institutional investors of 6,266,787 shares of the Company’s common stock, at a purchase price of $0.5585 per share and associated warrant. The Company also issued 6,266,787 unregistered warrants to the institutional investors in a concurrent private placement to purchase one share of common stock for each share of common stock purchased with an exercise price of $0.4335 per share. The gross proceeds to Diffusion, before deducting placement agent fees and other offering expenses, were approximately $3.5 million. The warrants are exercisable upon issuance and will expire five and one half years following the date of issuance.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offerings.

Diffusion currently intends to use the net proceeds from the offering to fund research and development of its lead product candidate, TSC, including clinical trial activities, and for general corporate purposes.

The shares of common stock (but not the warrants or the shares of common stock underlying the warrants) were offered pursuant to a “shelf” registration statement on Form S-3 (File No. 333-231541), which was declared effective by the Securities and Exchange Commission (SEC) on May 22, 2019. A prospectus supplement and the accompanying prospectus relating to the registered direct offering were filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue 3rd Floor, New York, New York 10022, or by calling (646) 975-6996 or by emailing This email address is being protected from spambots. You need JavaScript enabled to view it. or at the SEC’s website at http://www.sec.gov.

The warrants and shares issuable upon exercise of the warrants offered in the concurrent private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. is an innovative biotechnology company developing new treatments that improve the body’s ability to bring oxygen to the areas where it is needed most, offering new hope for the treatment of life-threatening medical conditions.

Diffusion’s lead drug TSC was originally developed in conjunction with the Office of Naval Research, which was seeking a way to treat hemorrhagic shock caused by massive blood loss on the battlefield.

Evolutions in research have led to Diffusion’s focus today: Fueling Life by taking on some of medicine’s most intractable and difficult-to-treat diseases, including stroke and GBM brain cancer. In each of these diseases, hypoxia – oxygen deprivation of essential tissue in the body – has proved to be a significant obstacle for medical providers and is the target for TSC’s novel mechanism.

In July 2019 the Company reported favorable safety data in a 19-patient dose-escalation run-in study to its Phase 3 INTACT program, using TSC to target inoperable GBM. Further findings from the dose-escalation run-in study, released in December 2019, also showed signals of enhanced survival and patient performance. Diffusion’s on-ambulance PHAST-TSC trial for acute stroke has begun patient enrollment. In addition, preclinical data supports the potential for TSC as a treatment for other conditions where hypoxia plays a major role, such as myocardial infarction, respiratory diseases such as COPD, peripheral artery disease, and neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.

Further, RES-529, the Company’s PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes, is in preclinical testing for GBM.

Diffusion is headquartered in Charlottesville, Virginia – a hub of advancement in the life science and biopharmaceutical industries – and is led by CEO David Kalergis, a 30-year industry veteran and company co-founder.

Forward-Looking Statements

To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds, as well as statements about the company's plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company's technology and product candidates, the anticipated timing of future clinical trials, and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the Diffusion’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include: Diffusion’s ability to maintain its Nasdaq listing, the use of proceeds of the offering, market conditions, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; general business and economic conditions; the company's need for and ability to obtain additional financing or partnering arrangements; and the various risk factors (many of which are beyond Diffusion’s control) as described under the heading “Risk Factors” in Diffusion’s filings with the United States Securities and Exchange Commission. All forward-looking statements in this news release speak only as of the date of this news release and are based on management's current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts:
David Kalergis, CEO
Diffusion Pharmaceuticals Inc.
(434) 220-0718
This email address is being protected from spambots. You need JavaScript enabled to view it.

LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
This email address is being protected from spambots. You need JavaScript enabled to view it.

NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Baozun, Inc. (“Baozun” or the “Company”) (NASDAQ: BZUN).   Such investors are advised to contact Robert S. Willoughby at This email address is being protected from spambots. You need JavaScript enabled to view it. or 888-476-6529, ext. 9980.

The investigation concerns whether Baozun and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 21, 2019, Baozun announced financial results for the third quarter of 2019 that were below market expectations and provided disappointing financial guidance for the fourth quarter of 2019, citing, in large part, the adverse “impact from terminating our service agreement with one electronics brand.”  Though Baozun did not disclose the identity of the “electronics brand” at issue, many members of the financial media have suggested that the disclosure referred to Huawei Technologies Co., Ltd. 

On this news, Baozun’s American Depository Receipt price fell $7.60 per share, or 17.47%, to close at $35.90 per share on November 21, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
This email address is being protected from spambots. You need JavaScript enabled to view it.
888-476-6529 ext. 9980

Seattle, Washington, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Wrapping up four days of cutting-edge education and motivation to help reinforce the strength of the “chain of survival,” the Citizen CPR Foundation leaves Seattle, WA issuing a nationwide call-to-action for the need for more citizen CPR training, greater access to AED’s and broader awareness of a national epidemic.

“We are arming citizens with the knowledge, training and motivation to save the lives of neighbors from the #1 homeland emergency they will face - sudden cardiac arrest,” says Dr. Vinay Nadkarni, President of the foundation.

Nearly 1,000 attendees gathered with the foundation and the America Heart Association, the American Red Cross, the Global Resuscitation Alliance, the Resuscitation Academy and numerous other leading, global non-profits and industry partners to bring world-renowned speakers and experts together at one conference. Learning the latest science, guidelines and techniques helps motivate and activate attendees to bring live-saving protocols back to their communities.

“Since our first conference on citizen CPR in Houston, TX in 1980, we have focused on bringing premier programming and high-quality, engaging content to a broad audience of professionals working in the field of SCA. Known for excellent speakers and cutting-edge science, we are now looking toward a future as an organization that develops and certifies “HEARTSafe Communities” and empowers citizens to act!”

Celebrations, recognition and awards brought energy and excitement to the event. The CPR Saves Live Rock ‘N’ Roll Celebration entertained the crowd with musical impersonators and moved them with a tribute to survivors and to those who have lost their life to SCA. Jennifer Hayes - a CPR coordinator whose own life and that of her unborn son were saved by CPR and proper response protocols - received the Hans H. Dahll Award for service to the field and raising awareness. The Medic One Foundation’s survivor gathering and mass CPR training event hosted a venue for local survivors to connect, and provided free CPR training for Seattle citizens.

Said Dr. Nadkarni, “we are on a mission to bring nationwide attention to both the epidemic, and the solution. CPR saves lives!”

About Citizen CPR Foundation 

Founded in 1987, the mission of Citizen CPR Foundation is to save lives from sudden cardiac arrest by stimulating effective community, professional and citizen action. Every two years, the foundation holds its international Cardiac Arrest Survival Summit, formerly the Emergency Cardiovascular Care Update (ECCU), which features the latest information and trends in cardiopulmonary resuscitation (CPR). Contact Jennifer Crocker at 816-916-6843 or This email address is being protected from spambots. You need JavaScript enabled to view it. for more information.

Attachments

• 34C8711B-C759-4999-90E5-C8F9312EC603_1_201_a
• 8E0FEB8D-89B1-4F8F-B2E4-4A6FEC2355B3_1_201_a

Jennifer Crocker
Citizen CPR Foundation
816-916-6843
This email address is being protected from spambots. You need JavaScript enabled to view it.

LOS ANGELES, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 6, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of UP Fintech Holding Limited (“UP Fintech” or the “Company”) (NASDAQ: TIGR) investors who acquired: (a) UP Fintech American Depository Shares (“ADSs”) pursuant and/or traceable to the Company’s initial public offering (“IPO”) conducted on or about March 20, 2019; or (b) UP Fintech securities between March 20, 2019 and May 16, 2019, inclusive (the “Class Period”).

If you are a shareholder who suffered a loss, click here to participate.

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to This email address is being protected from spambots. You need JavaScript enabled to view it., or visit our website at www.glancylaw.com.

In March 2019, UP Fintech completed its IPO in which it sold over 14.95 million ADSs for $8.00 per share.

On May 17, 2019, the Company announced its first quarter 2019 financial results and disclosed a 4.1% decrease in commissions. Moreover, the Company revealed that its operating costs skyrocketed by over 36%, citing increases in expenses related to employee headcount, employee compensation, office space, and leasehold improvements.

On this news, the Company’s ADS price fell $1.21 per share, or over 17%, to close at $5.77 per share on May 17, 2019, thereby injuring investors. Since the IPO, UP Fintech ADSs have traded as low as $4.18 per share, or 48% below the IPO price.

The complaint filed in this class action alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that before and/or at the time of the IPO, the Company was experiencing a material decrease in commissions because of a negative trend related to risk-averse investors in the market; (2) that the Company was unable to absorb costs associated with the rapid growth of its business and its status as a publicly listed company on a U.S. exchange; (3) that, as a result of the foregoing, the Company significantly increased its operating costs and expenses and net loss attributable to the Company; and (4) that as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased or otherwise acquired UP Fintech securities during the Class Period, you may move the Court no later than January 6, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to This email address is being protected from spambots. You need JavaScript enabled to view it., or visit our website at www.glancylaw.com.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.glancylaw.com